MIR100HG and osteosarcoma: Accumulating researchers have reported that MIR100HG is upregulated in many malignant tumors, containing leukemia, head and neck carcinoma, breast carcinoma, pancreatic ductal adenocarcinoma, osteosarcoma, gastric cancer, colorectal cancer, hepatocellular carcinoma and downregulated in a few tumors, including lung cancer, papillary thyroid cancer, and cervical cancer.